You are using an old and unsupported browser. Upgrade to a modern browser for a better experience

Times are shown in your local time zone (GMT )
Export Sessions

*subject to change*

Explore our Program

Filter & Search
Close Filter
Filters
Clear
Session Type
Session
Rooms
Day 1
Day 2
Session - - 30.0 mins -
To date, no causative treatments are available for common neurodegenerative diseases like Parkinson’s disease (PD). Previously failed trials did not account for the clinical and pathophysiological heterogeneity of PD. Genetics of PD provided first insight into the complexity of this most common neurodegenerative movement disorder and delineated relevant subgroups of patients, who share an underlying molecular pathology. Novel patient-based models from monogenic forms of PD allowed to dissect mechanisms of neurodegeneration and define a first entry point to screen for disease-modifying compounds for more targeted therapies. Using neurons derived from induced pluripotent stem cells we implemented a comprehensive high-troughput/high-content screening (HTS/HCS) platform for discovering neuroprotective compounds in monogenic forms of PD. Here we provide first promising results to identify mechanism-based interventions in subgroups of PD patients using advanced cellular models.

During the last years, there has been a rapid evolution in novel technologies, e.g. next generation sequencing technologies or device-assisted registrations of PD symptoms. This is linked with a dramatic increase in high quality data characterizing PD at different levels and enables novel strategies for patient stratification and identification of markers for therapeutic outcome, that can be translated into precision medicine approaches and clinical decision support. Here we provide evidence for genetic predictors of therapeutic outcome in PD. These implementation of novel technologies allow for a more direct participation of patients in ongoing research and strengthen patient’s autonomy and responsibility for future research.
 
Keywords:
genetic stratification, induced pluripotent stem cells, deep phenotyping, device-based assessments, stratified treatment, clinical decision support
Session - - 20.0 mins -
Session - - 150.0 mins - Room 1
A consumer and researcher discuss the use of medicinal cannabis for pain relief.  There are risks and benefits associated with the use of cannabis for people with PD. Come and find out about the latest research and a patients journey with medicinal cannabis.
Full details on this presentation to come
A panel discussion with medical researchers Professor John Mitrofanis, Dr Daniel Johnstone and Luke Gordon about the use of red to near-infrared light for the treatment of Parkinson’s disease, termed Photobiomodulation. Where is the research at and where is it headed?
Session - - 150.0 mins - Room 2
As the symptoms of Parkinson’s progress it can impact how you do a wide range of things including work. That doesn’t always mean you have to stop work before you are ready, or that your employer can dismiss you if you need adjustments to your role.  It is important to understand your rights in the workplace, including when you might disclose your condition and what your employer should do to keep you in your job. 
 
For some though, the impact of symptoms can mean continuing to work is not possible. Understanding your rights and entitlements when leaving the workforce is just as important, including knowing when and how to successfully claim on the valuable lump sum insurance most of us have through our superannuation fund. 
 
Looking beyond work, estate planning is an essential part of making sure you control who makes decisions for you and how your family is protected.  Appointing decision makers who can assist you if you are unable to make decisions for yourself can provide certainty and positively impact your wellbeing and quality of life. 
 
Experts from Maurice Blackburn Lawyers will be sharing their insights and answering your questions on all these issues and more. 
Full details on this presentation to come
Full details on this session to come
Session - - 150.0 mins - Room 3
An update on the potential and challenges for development of a safe and effective stem cell based therapy as a new treatment option for PD. 
Full details on this presentation to come
Olivia Nassaris will host Dr Fiona Kerr to discuss the neurophysiology of the interaction between people and people, and people and technology; how we shape each other, how technology shapes us, and how we should shape future technology. Beginning with the pillars of neurogenesis which is used as a strategic basis to shape the support services of Parkinson’s SA & NT and delving into what role does tech have in the lives of people living with Parkinson’s.
Full details on this session to come
Session - - 5.0 mins -
#Parkinson's Australia National Symposium - Prosper 2020
Parkinson's Australia National Symposium 'Prosper' 2020
#Parkinson's Australia National Symposium - Prosper 2020
Home